Rheumatoid arthritis

Assertio Holdings, Inc. (ASRT) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against Assertio Holdings, Inc.

Retrieved on: 
Friday, January 12, 2024

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Assertio Holdings, Inc. (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Assertio Holdings, Inc. (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, January 9, 2024

Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Monday, January 8, 2024

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Assertio Holdings, Inc. (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023.

Key Points: 
  • SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Assertio Holdings, Inc. (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
Monday, January 8, 2024

HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.

Key Points: 
  • Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
    HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
  • Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”.
  • “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date.
  • SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46).

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

Retrieved on: 
Monday, January 8, 2024

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today outlined key objectives and anticipated milestones for 2024 and provided an overview of recent progress in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • A webcast of Nurix’s ASH presentation is available in the Investors section of the Nurix website under Events and Presentations .
  • Nurix is evaluating daily oral dosing of NX-5948 in a Phase 1a/1b clinical trial in patients with relapsed or refractory B-cell malignancies.
  • Nurix plans to present and publish preclinical work on its wholly owned programs throughout 2024 at appropriate scientific and medical meetings.
  • Research milestones: Nurix expects to achieve multiple research collaboration milestones throughout 2024 from its existing collaborations with Gilead, Sanofi, and Pfizer.

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Kiniksa Pharmaceuticals Provides Corporate Update

Retrieved on: 
Thursday, January 4, 2024

HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.

Key Points: 
  • HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.
  • In fact, at the end of 2023 Kiniksa penetrated approximately 9% into the multiple-recurrence population, compared to approximately 5% at the end of 2022,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa.
  • Kiniksa has now completed enrollment in a fourth cohort (Cohort 4) of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Kiniksa is now evaluating potential partnership opportunities to advance development of mavrilimumab, which has generated positive data in mid-stage clinical trials across multiple indications.

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
Thursday, January 4, 2024

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases

Retrieved on: 
Wednesday, January 3, 2024

These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."

Key Points: 
  • These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."
  • Members of the SAB include:
    Peter Lipsky, M.D., served on the Board of Directors of the American College of Rheumatology.
  • She was President of the American College of Rheumatology, President of the Henry Kunkel Society, and Chair of the Scientific Advisory Board of the Lupus Research Alliance.
  • "AbelZeta is advancing promising new therapies for inflammatory and immunological diseases through innovative cell therapy platforms that provide custom-tailored treatment for each individual patient.

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 19, Status: Authorised